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ABSTRACT
Trigeminal neuralgia (TN) or Tic douloureux is a disorder  charac-
terized by stabbing or electric-shock-like pain in parts of the 
face. The presented research evaluates  the use of gabapentin 
and pregabalin with carbamazepine to relieve neuropathic pain 
in this condition.
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InTRoduCTIon
Trigeminal neuralgia (TN) or Tic douloureux is a disorder 
characterized by stabbing or electric-shock-like pain in 
parts of the face. The most accepted medical management 
of trigeminal neuralgia is antiepileptic drugs and carbama-
zepine is widely prescribed and used for the same. Among 
the antiepileptic drugs advised, gabapentin and pregabalin 
have been evaluated as a medication to relieve neuropathic 
pain with variable results.1-3 This study evaluates carbama-
zepine for controlling pain in trigeminal neuralgia indivi-
dually and in combination with gabapentin and pregabalin.
MATeRIAlS And MeThodS
Fourty patients with clinically proven TN were included 
in this study with a written informed consent from all the 
study patients. Ten of each study patient were randomly 
allocated to the four study groups, summarized in Table 1. 
A base line total blood cell count and a differential blood 
cell count was performed for all patients. All the study group 
patients were given five point pain scale chart, every week, 
for 4 weeks for evaluation. All patients filled a pain scale 
chart after a week. All the study medication were given in 
twice daily dosage for the study period and no adjustments 
in the dosage was done within the study period. The mean of 
four pain scores readings for 4 weeks was calculated for 
each patient. Finally mean pain score for each study group 
(mean of 10 patients) with standard deviation was calculated 
for intergroup comparisons. 
ReSulTS
The pain score values in the four study groups are summa-
rized in Table 2. The mean pain score values with standard 
deviation is shown in Table 3. The pain scores were found 
maximum in the placebo group (Group IV) and minimum 
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Table 1: Study groups
Group Medication
I Carbamazepine (100 mg BD)
II Carbamazepine (100 mg BD), Gabapentin (300 mg BD)
III Carbamazepine (100 mg BD), Gabapentin (300 mg BD) 
and Pregabalin (75 mg BD)
IV Placebo
Table 2: Pain scores
Group I Group II Group III Group IV
2.5 2.25 1.5 4.25
1.75 2.5 2.25 3.5
2 1.75 2.25 5
1.25 1 4.25 3.25
2.75 2.5 2.5 4
3.25 1.75 2 2.25
4.25 2.75 1.75 3
2.75 3 2.5 3.5
2.25 4.25 1.75 1.25
4 2.25 2.75 4.25
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in Group III where a combination of Carbamazepine 
(100 mg BD), Gabapentin (300 mg BD) and Pregabalin 
(75 mg BD) indicating a benefit of adding additional drug 
to carbamazepine for pain control. Group II showed a better 
pain control than patients only on carbamazepine in group I. 
Total blood cell count and a differential blood cell count 
for all the study patients were within normal limits at the 
end of the study.
dISCuSSIon
Management of trigeminal neuralgia with pharmacotherapy 
is instituted for all patients with this disorder before any 
interventional therapy is attempted for pain relief. Carbama-
zepine , an antiepileptic, is a well established drug in the 
treatment of TN. Various studies and authors have repor-
ted variable benefit and relapse rates in patients with TN 
with carbamazepine. There is evidence that pregabalin and 
gabapentin are effective in the neuralgic pain.3,4 We designed 
a randomized placebo controlled trial to assess the efficacy 
of pregabalin and gabapentin in addition to carbamazepine. 
Pérez C et al studied pregabalin as a pain alleviating 
medication and concluded on the benefits of this drug in 
neuropathic pain.5 Similarly Cheshire in his retrospective 
study and suggested that gabapentin can be effective as first 
or second line treatment of trigeminal neuralgia, even in 
cases resistant to traditional treatment modalities.3 Present 
study highlights the additive effect of both pregabalin and 
gabapentin to carbamazepine. The study group with prega-
balin and gabapentin added to carbamazepine demonstrated 
minimum weekly episodes of pain with lesser intensity. The 
exact in vivo mechanism of this synergistic effect of the study 
drugs needs evaluation. 
The study sample evaluated the study groups in a single 
center setup, for validation of these findings a multicentric 
placebo controlled trial is recommended. Addition of prega-
balin and gabapentin to carbamazepine showed better clinical 
response in terms of reduction of weekly episodes of pain 
with reduced intensity with each additional drug added to 
carbamazepine.
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Table 3: Mean pain scores (±SD)
Group I 2.67 ± 095
Group II 2.40 ± 0.86
Group III 2.35 ± 0.77
Group IV 3.42 ± 0.08
